
An artist’s concept of the nanotrap in action. The nanotrap is shown with a yellow core, green phospholipid shell, and red functionalized particles to bind the virus (shown in gray, decorated with their infamous spike protein in green).
Image courtesy Chen and Rosenberg et al.
Made of FDA-approved polymers and phospholipids, the nanoparticles are about 500 nanometers in diameter—much smaller than a cell. That means the nanotraps can reach more areas inside the body and more effectively trap the virus.
Then, to check to make sure the tiny particles looked the way they expected, they partnered with the lab of Assoc. Prof. Bozhi Tian to use electron microscopes to get a good look. “From our imaging, we saw a solid core and a lipid bilayer shell. That’s the essential part because it mimics the cell,” said Tian, who is appointed in the Department of Chemistry.
The researchers tested the safety of the system in a mouse model and found no toxicity. They then tested the nanotraps against a pseudovirus—a less potent model of a virus that doesn’t replicate—in human lung cells in tissue culture plates and found that they completely blocked entry into the cells.
Once the pseudovirus bound itself to the nanoparticle—which in tests took about 10 minutes after injection—the nanoparticles used a molecule that calls the body’s macrophages to engulf and degrade the nanotrap. Macrophages will generally eat nanoparticles within the body, but the nanotrap molecule speeds up the process. The nanoparticles were cleared and degraded within 48 hours.
The researchers also tested the nanoparticles with a pseudovirus in an ex vivo lung perfusion system—a pair of donated lungs that is kept alive with a ventilator—and found that they completely blocked infection in the lungs.
They also collaborated with researchers at Argonne National Laboratory to test the nanotraps with a live virus (rather than a pseudovirus) in an in vitro system. They found that their system inhibited the virus 10 times better than neutralizing antibodies or soluble ACE2 alone.
A potential future treatment for COVID-19 and beyond
Next the researchers hope to further test the system, including more tests with a live virus and on the many virus variants.
“That’s what is so powerful about this nanotrap,” Rosenberg said. “It’s easily modulated. We can switch out different antibodies or proteins or target different immune cells, based on what we need with new variants.”
The nanotraps can be stored in a standard freezer and could ultimately be given via an intranasal spray, which would place them directly in the respiratory system and make them most effective.
The nanotraps can be stored in a standard freezer and could ultimately be given via an intranasal spray.
The researchers say it is also possible to serve as a vaccine by optimizing the formulation.
“This nanomaterial engineering approach provides a versatile platform to clear viruses, and paves the way for designing next-generation vaccines and therapeutics,” said co-author and graduate student Jiuyun Shi.
“This is the starting point,” Huang said. “We want to do something to help the world.”
Original Article: UChicago scientists design ‘nanotraps’ to catch and clear coronavirus from tissue
More from: University of Chicago | Argonne National Laboratory
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nanotraps capture SARS-CoV-2
- Researchers find deer carry SARS-CoV-2 variants that are extinct in humans
Cornell University researchers have found that white-tailed deer—the most abundant large mammal in North America—are harboring SARS-CoV-2 variants that were once widely circulated, but no ...
- Implications of SARS-CoV-2 immunological evasion
In a recent study posted to the medRxiv* preprint server, researchers modeled the implications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunological evasion. Study ...
- Evolutionary history of SARS-CoV-2 leads to a universal vaccine already being tested in animal models
By taking inspiration from the evolutionary history of SARS-CoV-2 itself, scientists in China have crafted a new vaccine that, at least in animal models, provides protection against omicron and an ...
- Broad Range Antibodies Neutralize All SARS-CoV-2 Variants and Other Coronaviruses
Coldspot-guided method identified antibodies against highly conserved SARS-CoV-2 epitopes that recognize all variants and other coronaviruses.
- DiPentima: Why SARS-CoV-2 and COVID-19 are here to stay. And what we must do about it.
In epidemiology an endemic disease is defined as the constant presence of a disease (COVID-19) or an infectious agent (SARS-CoV-2) within a given geographic area or population group. Unfortunately ...
Go deeper with Google Headlines on:
Nanotraps capture SARS-CoV-2
[google_news title=”” keyword=”nanotraps capture SARS-CoV-2″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanotraps
- Indian Namaste the Preferred Greeting over Conventional Handshake - Latest News and Research Updates
Keep abreast with the latest news related to Indian Namaste the Preferred Greeting over Conventional Handshake there are 3379 news items on Indian Namaste the Preferred Greeting over Conventional ...
Go deeper with Google Headlines on:
Nanotraps
[google_news title=”” keyword=”nanotraps” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]